← Leaderboards
Xianglin Du
University Of Texas Hlth Sci Ctr Houston
$6,062,197
Attributed
$6,062,197
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $941K · FY2007–24$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,202,720 · 3
AHRQ$1,859,477 · 2
By mechanism
R01$6,062,197 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Eric A Boerwinkle$148,432,538
- Charles Erwin Ford$742,500
- Lorraine Q. Frazier$2,996,604
- Barry Davis$10,898,715
- Kangho Kim$1,934,400
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposIncidencePublic Health RelevancePreventRisk FactorsMedicare ClaimComorbidityMalignant NeoplasmsLinkPharmaceutical PreparationsFollow-UpRecording Of Previous EventsAffectMonitorMedicareHypertensionCause Of DeathAntihypertensive AgentsAgedHuman Old Age (65+)Age-Associated Memory ImpairmentHigh PrevalenceBreast NeoplasmsHazard
Grant awards (23)
The Risk of Developing Alzheimerâs Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries$312,000
R01 · FY2024 · AG · contact PI
The Risk of Developing Alzheimerâs Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries$312,000
R01 · FY2023 · AG · contact PI
The Risk of Developing Alzheimerâs Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries$312,000
R01 · FY2022 · AG · contact PI
Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial Participants$331,100
R01 · FY2021 · AG · contact PI
The Risk of Developing Alzheimerâs Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries$312,000
R01 · FY2021 · AG · contact PI
Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial Participants$331,100
R01 · FY2020 · AG · contact PI
The Risk of Developing Alzheimer's Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries$310,666
R01 · FY2020 · AG · contact PI
Blood Pressure Control and Antihypertensive Drugs in ALLHAT Trial Participants and the Risk of Alzheimers Disease and Related dementias$299,245
R01 · FY2020 · AG · contact PI
Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial Participants$331,100
R01 · FY2019 · AG · contact PI
Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial Participants$331,100
R01 · FY2018 · AG · contact PI
Comparative Effectiveness and Cost Effectiveness of Cancer Chemotherapy$293,642
R01 · FY2014 · HS · contact PI
Comparative Effectiveness and Cost Effectiveness of Cancer Chemotherapy$290,305
R01 · FY2013 · HS · contact PI
Comparative Effectiveness and Cost Effectiveness of Cancer Chemotherapy$296,079
R01 · FY2012 · HS · contact PI
Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy$208,986
R01 · FY2010 · HS · contact PI
Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy$252,612
R01 · FY2009 · HS · contact PI
Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy$246,360
R01 · FY2008 · HS · contact PI
Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy$271,493
R01 · FY2007 · HS · contact PI
Evaluation of Chemotherapy Claims for Breast Cancer$193,867
R01 · FY2003 · CA
Evaluation of Chemotherapy Claims for Breast Cancer$173,515
R01 · FY2003 · CA
Evaluation of Chemotherapy Claims for Breast Cancer$40,808
R01 · FY2003 · CA
Evaluation of Chemotherapy Claims for Breast Cancer$234,675
R01 · FY2002 · CA
Evaluation of Chemotherapy Claims for Breast Cancer$142,869
R01 · FY2002 · CA
Evaluation of Chemotherapy Claims for Breast Cancer$234,675
R01 · FY2001 · CA